Catalyst Wire Dossier Catalyst Wire Dossier

Imipenem+cilastatin/relebactam (MK-7655A)

imipenem/cilastatin/relebactam · Merck Sharp & Dohme LLC
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Imipenem+cilastatin/relebactam (MK-7655A), covering 2019-09-17 to 2019-09-17. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) in Japanese Participants With Complicated Intra-abdominal Infection or Complicated Urinary Tract Infection (MK-7655A-017) [Phase 3]

See pricing